Fecal Calprotectin Concentrations in Cats with Chronic Enteropathies

Diagnosis of feline chronic inflammatory enteropathies (CIE) and the differentiation from small cell intestinal lymphoma (SCL) can be challenging. Intestinally expressed calprotectin (S100A8/A9 protein complex) appears to be part of the complex pathogenesis of feline chronic enteropathies (FCE). Fec...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary sciences 2023-06, Vol.10 (7), p.419
Main Authors: Riggers, Denise S, Xenoulis, Panagiotis G, Karra, Dimitra A, Enderle, Lena L, Köller, Gabor, Böttcher, Denny, Steiner, Joerg M, Heilmann, Romy M
Format: Article
Language:English
Subjects:
Analysis
Animal welfare
Biomarkers
Biopsy
Cats
Cell differentiation
Disease
Dogs
Endoscopy
Feces
food-responsive enteropathy
gastrointestinal diet
Gastrointestinal diseases
Histology
hydrolyzed diet
Inflammation
Inflammatory bowel disease
Intestine
Laboratories
Lymphoma
Lymphomas
Medical research
Medicine, Experimental
Pathogenesis
Questionnaires
small cell lymphoma
steroid-responsive enteropathy
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diagnosis of feline chronic inflammatory enteropathies (CIE) and the differentiation from small cell intestinal lymphoma (SCL) can be challenging. Intestinally expressed calprotectin (S100A8/A9 protein complex) appears to be part of the complex pathogenesis of feline chronic enteropathies (FCE). Fecal calprotectin is a non-invasive biomarker for intestinal inflammation in humans and dogs but has not yet been evaluated in cats. We hypothesized that fecal calprotectin (fCal) concentrations are increased in FCE, correlate with clinical and/or histologic disease severity, and distinguish cases of CIE from SCL. This case-control study included fecal samples and patient data from cats with CIE ( = 34), SCL ( = 17), other gastrointestinal (GI) diseases ( = 16), and cats with no clinical signs of GI disease ( = 32). fCal concentrations were measured using the immunoturbidimetric fCal turbo assay (Bühlmann Laboratories). Compared to healthy cats, fCal concentrations were significantly increased in CIE, SCL, and other diseases (all < 0.0001), but were not different between these three groups (all > 0.05), or between cats with extra-GI diseases and healthy controls. These findings suggest that fCal may have utility as a clinical biomarker for FCE but not for intestinal disease differentiation. It further supports the role of calprotectin in the pathogenesis of the spectrum of FCE, which includes CIE and SCL.
ISSN:2306-7381
2306-7381
DOI:10.3390/vetsci10070419